Expression level of vascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinib

Taguchi, Tomoaki; Miyake, Hideaki; Kusuda, Yuji; Fujisawa, Masato

doi:10.1016/j.urolonc.2011.02.012

Cited by 39 publications

(31 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Even at genetic level, novel studies have revealed a differential outcome based on the presence of polymorphisms in VEGF and VEGFR genes (Scartozzi et al , 2013) or based on miRNA expression profiles (Gamez-Pozo et al , 2012). Terakawa et al (2013) suggested that it would be useful to consider the expression levels of KDR to identify the metastatic RCC patients likely to be benefited from treatment with sunitinib; although several biomarkers were studied, only VEGFR2 expression appeared to be independently related to PFS as well as OS on multivariate analysis. In the analysis carried out in our panel of patients, we described for the first time the correlation of pKDR-Y1175 expression with PFS and OS in patients with metastatic RCC in terms of clinical benefit of sunitinib-based therapy.…”

Section: Discussionmentioning

confidence: 99%

Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy

et al. 2014

View full text Add to dashboard Cite

Background:Sunitinib represents a widely used therapy for metastatic renal cell carcinoma patients. Even so, there is a group of patients who show toxicity without clinical benefit. In this work, we have analysed pivotal molecular targets involved in angiogenesis (vascular endothelial growth factor (VEGF)-A, VEGF receptor 2 (KDR), phosphorylated (p)KDR and microvascular density (MVD)) to test their potential value as predictive biomarkers of clinical benefit in sunitinib-treated renal cell carcinoma patients.Methods:Vascular endothelial growth factor-A, KDR and pKDR-Y1775 expression as well as CD31, for MVD visualisation, were determined by immunohistochemistry in 48 renal cell carcinoma patients, including 23 metastatic cases treated with sunitinib. Threshold was defined for each biomarker, and univariate and multivariate analyses for progression-free survival (PFS) and overall survival (OS) were carried out.Results:The HistoScore mean value obtained for VEGF-A was 121.6 (range, 10–300); for KDR 258.5 (range, 150–300); for pKDR-Y1775 10.8 (range, 0–65) and the mean value of CD31-positive structures for MVD visualisation was 49 (range, 10–126). Statistical differences for PFS (P=0.01) and OS (P=0.007) were observed for pKDR-Y1775 in sunitinib-treated patients. Importantly, pKDR-Y1775 expression remained significant after multivariate Cox analysis for PFS (P=0.01; HR: 5.35, 95% CI, 1.49–19.13) and for OS (P=0.02; HR: 5.13, 95% CI, 1.25–21.05).Conclusions:Our results suggest that the expression of phosphorylated (i.e., activated) KDR in tumour stroma might be used as predictive biomarker for the clinical outcome in renal cell carcinoma first-line sunitinib-treated patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Pretreatment tumor expression of VEGFR-2 (either moderate or strong immunohistochemical staining intensity in >10% of tumor cells) has been independently associated with increased PFS in 40 patients with advanced RCC treated with sunitinib (HR, 2.91; 95% CI, 1.15-7.41; P ¼ 0.0025; ref. 47). A small exploratory study of primary tumors from 23 patients with mRCC also found that pretreatment gene expression of VEGF isoforms VEGF 121 and VEGF 165 was associated with response to sunitinib at 3 months (P ¼ 0.04 for both; ref.…”

Section: Tumor Tissue Biomarkersmentioning

confidence: 96%

Molecular Biomarkers in Advanced Renal Cell Carcinoma

Maroto

Rini

2014

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…Recently, it has been proposed that combination therapy with TKIs of VEGFR, such as sorafenib and sunitinib and the mTOR inhibitors, vatalanib and everolimus, is effective and tolerable for patients suffering from mRCC 19. Terakawa et al20 suggested that VEGFR-2 is the most significant factor in PFS of mRCC in a study involving a total of 40 patients with mRCC after radical nephrectomy. It has been shown in a registry-based analysis that anti-VEGFR agents are effective in improving the prognosis of mRCC 21.…”

Section: Discussionmentioning

confidence: 99%

The effect of apatinib in the treatment of metastatic renal cell carcinoma: a case report and review of the literature

Bi¹,

Liu²,

Huang³

2017

IMCRJ

View full text Add to dashboard Cite

The aim of this study was to explore the effect of apatinib in the treatment of metastatic renal cell carcinoma (mRCC) and related adverse events. A case of mRCC was reported which recurred after surgery and roferon treatment. The patient was treated with apatinib at a dose of 500 mg orally, twice daily, 28 days/cycle. The metastatic lesions improved based on computed tomography after apatinib administration in the fourth and eighth month. The progression-free survival of the patient had increased almost to 8 months. The patient showed a good tolerance with only an adverse effect of mild-to-moderate hand-foot syndrome which was managed well. Apatinib is an option for mRCC after previous treatment. However, more and larger trials are still needed.

show abstract

Expression level of vascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinib

Cited by 39 publications

References 22 publications

Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy

Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy

Molecular Biomarkers in Advanced Renal Cell Carcinoma

The effect of apatinib in the treatment of metastatic renal cell carcinoma: a case report and review of the literature

Contact Info

Product

Resources

About